Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

By A. Grothey, Eric Van Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone and 10 more. The Lancet, 2013

2,631 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/3946becddb85f70009ea8fffb1e1925d19bf0639

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. L. Diaz
2. Kenneth W. Kinzler
3. Huanhuan Chen
4. Li-li Zheng
5. Zhenling Liu
6. Li-Ping Sun
7. Lei Shi
8. N. Vasudev

In Oncology

1. Janis Taube
2. D. Pardoll
3. Kenneth W. Kinzler
4. N. Vasudev
5. Andrew K. Joe
6. Andrew R Reynolds
7. Rakesh K. Jain
8. Lieping Chen

Citations in the corpus

• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “94) 1 [111] 2nd line chemotherapy +/bevacizumab ML18147 2nd line beyond progression on bevacizumab OS 9.”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Regorafenib versus placebo CORRECT [31] Improvement in OS”
• Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade (2017, background): “The estimates of OS at 1- and 2-years were 76% and 64%, respectively, which is markedly higher than expected based on the advanced state of disease in this cohort (21).”
• Ten years of anti-vascular endothelial growth factor therapy (2016, neutral): “…RTKI and RAF kinase inhibitor regorafenib (Stivarga; Onyx, Bayer) 124 is the only kinase inhibitor to be approved by the FDA as a monotherapy for previously treated metastatic colorectal cancer (February 2013) following improved OS in the CORRECT placebo-controlled Phase III study 125 .”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “• Commonly used anticancer drugs that have been approved for the indication of colorectal cancer and are covered by the Japanese National Health Insurance include the followings: Cytotoxic drugs: fluorouracil (5‑FU), 5‑FU + levofoli‑ nate calcium (l‑LV), tegafur uracil (UFT), tegafur gimer‑ acil ote”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Regorafenib has shown efficacy in patients pretreated with all other options in a large phase III trial, where it prolonged OS compared with placebo [I, B] [23].”